Higher topoisomerase 2 alpha gene transcript levels predict better prognosis in GBM patients receiving temozolomide chemotherapy: Identification of temozolomide as a TOP2A inhibitor

Journal of Neuro-Oncology

Volumn 107, Issue 2, 2012, Pages 289-297

  Arivazhagan, A ^a   Kumar, Durairaj Mohan ^b   Sagar, Vinay ^c   Patric, Irene Rosita Pia ^b   Sridevi, S ^b   Thota, Balaram ^a   Srividya, Mallavarapu R ^a   Prasanna, K ^d   Thennarasu, K ^a   Mondal, Neelima ^c   Hegde, A S ^d   Chandramouli, B A ^a   Santosh, V ^a   Rao, M R S ^e   Kondaiah, P ^b   Somasundaram, K ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

^b INDIAN INSTITUTE OF SCIENCE   (India)

^c JAWAHARLAL NEHRU UNIVERSITY   (India)

^d SRI SATHYA SAI INSTITUTE OF HIGHER MEDICAL SCIENCES   (India)

^e JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH   (India)

Author keywords

Astrocytoma; Glioblastoma; Glioma; Prognosis; Temozolomide chemotherapy; TOP2A

Indexed keywords

CAMPTOTHECIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) ALPHA; DNA TOPOISOMERASE (ATP HYDROLYSING) BETA; DNA TOPOISOMERASE 3 ALPHA; ETOPOSIDE; MESSENGER RNA; PLASMID DNA; SMALL INTERFERING RNA; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DACARBAZINE; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; DRUG DERIVATIVE; GYRASE INHIBITOR; TUMOR ANTIGEN;

ARTICLE; ASTROCYTOMA; BRAIN TISSUE; CANCER CELL CULTURE; CANCER GRADING; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CELL STRAIN U251; COHORT ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SUPERCOILING; DRUG CYTOTOXICITY; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; GENE; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROSPECTIVE STUDY; PROTEIN FAMILY; TOPOISOMERASE 2 ALPHA GENE; UPREGULATION; BRAIN TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; FEMALE; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; MORTALITY; PROGNOSIS; TUMOR CELL LINE;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CAMPTOTHECIN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COHORT STUDIES; DACARBAZINE; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLIOBLASTOMA; HUMANS; MALE; PROGNOSIS; RNA, MESSENGER; TOPOISOMERASE II INHIBITORS;

EID: 84863582716     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0758-3     Document Type: Article

References (36)

1. Furnari FB, Fenton T, Bachoo RM et al (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21:2683-2710
2. Stewart LA (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011-1018
3. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466
4. Stevnsner T, Bohr VA (1993) Studies on the role of topoisomerases in general, gene- and strand-specific DNA repair. Carcinogenesis 14:1841-1850
5. Watt PM, Hickson ID (1994) Structure and function of type II DNA topoisomerases. Biochem J 303(Pt 3):681-695
6. Kasahara K, Fujiwara Y, Sugimoto Y et al (1992) Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines. J Natl Cancer Inst 84:113-118
7. Shpitz B, Bomstein Y, Zehavi T et al (2000) Topoisomerase II alpha expression in ductal carcinoma in situ of the breast: a preliminary study. Hum Pathol 31:1249-1254
8. Taniguchi K, Wakabayashi T, Yoshida T et al (1999) Immunohistochemical staining of DNA topoisomerase II alpha in human gliomas. J Neurosurg 91:477-482
9. Hao YJ, Natsume A, Mizuno M et al (2000) Correlation between DNA topoisomerase II alpha expression and sensitivity to etoposide in human glioma cell lines. Gan To Kagaku Ryoho 27:1403-1409
10. Hashimoto S, Chatterjee S, Ranjit GB et al (1995) Drastic reduction of topoisomerase II alpha associated with major acquired resistance to topoisomerase II active agents but minor perturbations of cell growth. Oncol Res 7:407-416
11. Asano T, An T, Mayes J et al (1996) Transfection of human topoisomerase II alpha into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene. Biochem J 319(Pt 1):307-313
12. Zhou Z, Zwelling LA, Ganapathi R, Kleinerman ES (2001) Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase II alpha gene transfer is independent of topoisomerase II beta. Br J Cancer 85:747-751
13. Zhou Z, Zwelling LA, Kawakami Y et al (1999) Adenovirusmediated human topoisomerase II alpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells. Cancer Res 59:4618-4624
14. Gobble RM, Qin LX, Brill ER et al (2011) Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesis. Cancer Res 71:2697-2705
15. Hart MG, Grant R, Garside R et al. (2008) Temozolomide for high grade glioma. CocHRane Database Syst Rev; CD007415
16. 6methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26:4189-4199
17. Mandraju RK, Kannapiran P, Kondapi AK (2008) Distinct roles of Topoisomerase II isoforms: DNA damage accelerating alpha, double strand break repair promoting beta. Arch Biochem Biophys 470:27-34
18. Jarvinen TA, Liu ET (2003) HER-2/neu and topoisomerase II alpha in breast cancer. Breast Cancer Res Treat 78:299-311
19. Wang JC (1996) DNA topoisomerases. Annu Rev Biochem 65:635-692
20. Isaacs RJ, Davies SL, Sandri MI et al (1998) Physiological regulation of eukaryotic topoisomerase II. Biochim Biophys Acta 1400:121-137
21. Yang X, Li W, Prescott ED et al (2000) DNA topoisomerase II beta and neural development. Science 287:131-134
22. Oda M, Arakawa Y, Kano H et al (2005) Quantitative analysis of topoisomerase II alpha to rapidly evaluate cell proliferation in brain tumors. Biochem Biophys Res Commun 331:971-976
23. Zhao H, Yu H, Liu Y et al (2008) DNA topoisomerase II-alpha as a proliferation marker in human gliomas: correlation with PCNA expression and patient survival. Clin Neuropathol 27:83-90
24. Ho DM, Hsu CY, Ting LT, Chiang H (2003) MIB-1 and DNA topoisomerase II alpha could be helpful for predicting long-term survival of patients with glioblastoma. Am J Clin Pathol 119:715-722
25. Faria MH, Goncalves BP, do Patrocinio RM et al (2006) Expression of Ki-67, topoisomerase IIalpha and c-MYC in astrocytic tumors: correlation with the histopathological grade and proliferative status. Neuropathology 26:519-527
26. Holden JA, Townsend JJ (1999) DNA topoisomerase II-alpha as a proliferation marker in astrocytic neoplasms of the central nervous system: correlation with MIB1 expression and patient survival. Mod Pathol 12:1094-1100
27. Jarvinen TA, Tanner M, Rantanen V et al (2000) Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 156:839-847
28. Gudkov AV, Zelnick CR, Kazarov AR et al (1993) Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. Proc Natl Acad Sci USA 90:3231-3235
29. Asano T, Zwelling LA, An T et al (1996) Effect of transfection of a Drosophila topoisomerase II gene into a human brain tumour cell line intrinsically resistant to etoposide. Br J Cancer 73:1373-1380
30. Vassetzky YS, Alghisi GC, Roberts E, Gasser SM (1996) Ectopic expression of inactive forms of yeast DNA topoisomerase II confers resistance to the anti-tumour drug, etoposide. Br J Cancer 73:1201-1209
31. Withoff S, Keith WN, Knol AJ et al (1996) Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel. Br J Cancer 74:502-507
32. Yan L, Bulgar A, Miao Y, Mahajan V, Donze JR, Gerson SL, Liu L (2007) Combined treatment with temozolomide and methoxyamine: blocking apurininc/pyrimidinic site repair coupled with targeting topoisomerase IIα. Clin Cancer Res 13:1532-1539
33. Reardon DA, Quinn JA, Rich JN et al (2005) Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer 104:1478-1486
34. Desjardins A, Reardon DA, Herndon JE et al (2008) Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 14:7068-7073
35. Leone S, Cornetta T, Basso E, Cozzi R (2010) Resveratrol induces DNA double-strand breaks tHRough human topoisomerase II interaction. Cancer Lett 295:167-172
36. Schmidt F, Knobbe CB, Frank B et al (2008) The topoisomerase II inhibitor, genistein, induces G2/M arrest and apoptosis in human malignant glioma cell lines. Oncol Rep 19:1061-1066